U.S. Astronomers Are Furious At Federal Funding 'Failures'

After years of passivity, the astronomy community is protesting telescope closings, cramped quarters, and scanty maintenance Like some ill solar wind, word is radiating through the galaxy of United States astronomers that they’ll have to shut down more of their small telescopes before plans to build a new one are approved. For many, this is the final straw. Throughout the past decade, U.S. astronomers suffered in silence as the National Science Foundation retargeted money to areas of s

Written byRobert Crease
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Like some ill solar wind, word is radiating through the galaxy of United States astronomers that they’ll have to shut down more of their small telescopes before plans to build a new one are approved. For many, this is the final straw.

Throughout the past decade, U.S. astronomers suffered in silence as the National Science Foundation retargeted money to areas of science likely to produce more practical payoffs. Most bit their tongues for example, during four years of flat funding, amounting to an annual budget reduction after inflation of 5%. Few protested frozen salaries, curtailments in observing time, breakups of effective research teams, deteriorating facilities, and cancellations of projects deemed critical to keep the U.S. astronomy program competitive.

But this spring, when Sidney Wolff, director of the National Optical Astronomy Observatories (NOAO), drew up contingency plans for operating with an additional 10% cut, the mood began to turn rebellious. Gripes ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies